| 1.45 0.02 (1.4%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.18 | 1-year : | 5.82 |
| Resists | First : | 3.58 | Second : | 4.98 |
| Pivot price | 1.77  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.41  |
MA(20) : | 2.36 |
| MA(100) : | 3.28 |
MA(250) : | 3.06 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 2.5 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 5.96 | Low : | 1.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SKYE ] has closed above bottom band by 41.0%. Bollinger Bands are 99.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.47 - 1.48 | 1.48 - 1.5 |
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Fri, 24 Oct 2025
Intraday pattern recognizer results for Skye Bioscience Inc. - Insider Selling & Verified Swing Trading Watchlist - newser.com
Fri, 24 Oct 2025
What technical models suggest about Skye Bioscience Inc.’s comeback - July 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
Fri, 24 Oct 2025
Will Skye Bioscience Inc. stock deliver consistent dividends - 2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Fri, 24 Oct 2025
Will Skye Bioscience Inc. (09R) stock announce a stock split - July 2025 Volume & Community Consensus Picks - newser.com
Fri, 24 Oct 2025
Published on: 2025-10-24 01:35:45 - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 66 (%) |
| Shares Short | 2,960 (K) |
| Shares Short P.Month | 2,740 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41 % |
| Return on Equity (ttm) | -72.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 1.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|